2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares - Archive ouverte HAL Access content directly
Journal Articles Joint Bone Spine Year : 2020

2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares

(1) , (2, 3) , (4) , (5) , (6) , (7) , (1) , , (8, 9) , (1) , (10) , (1) , (3) , (1) , (1)
1
2
3
4
5
6
7
8
9
10
René-Marc Flipo
  • Function : Author
Jacques Grichy
  • Function : Author

Abstract

Objective: To develop French Society of Rheumatology-endorsed recommendations for the management of gout flares. Methods: These evidence-based recommendations were developed by 9 rheumatologists (academic or community-based), 3 general practitioners, 1 cardiologist, 1 nephrologist and 1 patient, using a systematic literature search, one physical meeting to draft recommendations and 2 Delphi rounds to finalize them. Results: A set of 4 overarching principles and 4 recommendations was elaborated. The overarching principles emphasize the importance of patient education, including the need to auto-medicate for gout flares as early as possible, if possible within the first 12 h after the onset, according to a pre-defined treatment. Patients must know that gout is a chronic disease, often requiring urate-lowering therapy in addition to flare treatment. Comorbidities and the risk of drug interaction should be screened carefully in every patient as they may contraindicate some anti-inflammatory treatments. Colchicine must be early prescribed at the following dosage: 1 mg then 0.5 mg one hour later, followed by 0.5 mg , 2 to 3 times/day over the next days. In case of diarrhea, which is the first symptom of colchicine poisoning, dosage must be reduced. Colchicine dosage must also be reduced in patients with chronic kidney disease or taking drugs, which interfere with its metabolism. Other first-line treatment options are systemic/intra-articular corticosteroids, or non-steroidal anti-inflammatory agents (NSAIDs). IL-1 inhibitors can be considered as a second-line option in case of failure, intolerance or contraindication to colchicine, corticosteroids and NSAIDs. They are contraindicated in cases of infection and neutrophil blood count should be monitored. Conclusion: These recommendations aim to provide strategies for the safe use of anti-inflammatory agents, in order to improve the management of gout flares.
Fichier principal
Vignette du fichier
Latourte et al - 2020 - Recommandations 2020 de la SFR.pdf (1.04 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03491421 , version 1 (09-03-2022)

Identifiers

Cite

Augustin Latourte, Tristan Pascart, René-Marc Flipo, Gérard Chalès, Laurence Coblentz-Baumann, et al.. 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine, 2020, 87 (5), pp.387 - 393. ⟨10.1016/j.jbspin.2020.05.001⟩. ⟨hal-03491421⟩
35 View
62 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More